BioSpace News Archive

Aesyra SA Announces Closing of First Financing Round to Develop AesyBite™, a novel Dental Product that Monitors and Actively Reduces Bruxism

Aesyra SA is a private company based in Lausanne that is developing a medical device able to accurately monitor and relieve sleep bruxism, a highly prevalent condition without therapy that has negative impact on patient’s life and is associated with serious sleep disorders such as sleep apnea.

June 25, 2019
·
2 min read
Drug Development

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)

EpicentRx Inc. announced the publication of positive results from its Phase 2 clinical trial of RRx-001, a tumor associated macrophage repolarizing agent, in small cell lung cancer.

June 25, 2019
·
3 min read
Business

2019 Global Genes RARE Champion of Hope Award Recipients Announced

Nine Individuals and Organizations from Around the World will be Recognized for Their Positive Impact on the Rare Disease Community

June 25, 2019
·
3 min read
Business

SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer

SmartPharm Therapeutics announced that José Trevejo, MD, PhD, has been appointed Chief Executive Officer.

June 25, 2019
·
3 min read
Deals

Antibe Therapeutics Announces CEO Letter to Shareholders - June 25, 2019

Last year was pivotal for Antibe as we delivered dramatic gastrointestinal (“GI”) safety data for our lead drug, ATB-346, in a head-to-head Phase 2B study versus naproxen, the most prescribed NSAID in the United States.

June 25, 2019
·
7 min read
Drug Development

Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes

Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile

June 25, 2019
·
10 min read
Pharm Country

Valley Home Care Averages 6.25% 30-day All-Cause Readmission Rate over 12-months

Valley Home Care has achieved a 6.25% 30-day all-cause hospital readmission rate over 12 months from January through December of 2018.

June 25, 2019
·
3 min read
EY, Sensyne Health and Guardtime to use AI and blockchain to link health care reimbursement and actual patient outcomes

EY today announces plans to expand the current Health Outcomes Assessment platform through a collaboration with Sensyne Health and Guardtime.

June 25, 2019
·
4 min read
Pharm Country

Dr. Reddy’s Laboratories Announces the Launch of Tobramycin Inhalation Solution, USP in the U.S. Market

Dr. Reddy’s Laboratories Ltd. announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).

June 25, 2019
·
2 min read
Job Trends

Co-Diagnostics, Inc. Launches CE-Marked Multiplex Test at CARPHA 2019

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced the launch of their Logix Smart™ ZDC multiplex test at the 64th Annual 2019 Caribbean Public Health Agency Health Research Conference.

June 25, 2019
·
3 min read